The Atlantic Cancer Research Institute (ACRI) is a private, non-profit organization founded in 1998 and situated within the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. ACRI scientists are working with partners in Canada and around the world to impact patient care via the pursuit of research in the area of liquid biopsy and targeted treatment.

We have a research team of over 50 people who have expertise in genomics, proteomics, molecular biology, cell biology, immunology, bioinformatics, pathology, mass spectrometry as well in vitro and in vivo testing. Through its work, ACRI is contributing to the global research effort aimed at combating cancer.

**VISION**
Contribute to finding cures for cancer by being a leader in innovative research

**MISSION**
Understanding cancer and finding solutions:
- by fostering interdisciplinary research;
- by transferring scientific innovation towards patient care;
- by contributing to the training of future researchers.

**VALUES**
ACRI researchers will work in an independent but collaborative way that ensures we attract and retain a team that exemplifies collegiality, collaboration, professionalism, compassion and commitment.
MESSAGE FROM THE PRESIDENT & SCIENTIFIC DIRECTOR

Over the last 20 years, our talented team of dedicated personnel has continued its pursuit of research excellence in order to further our understanding of cancer, and apply that knowledge towards solutions for patients that are trying to overcome this disease. As we move forward to the next 20 years, our team is inspired and motivated by the courage of people affected by cancer, which in turn fuels our resolve to find solutions for this terrible disease.

Our vision and focus on precision medicine has led us to emerge among the leaders in the field, particularly in the area of liquid biopsy and new approaches to targeted treatment. Increasingly our efforts have been focused around the concepts of personalized medicine in cancer; a theme that centers around the specific characteristics of a patient’s cancer in order to tailor the appropriate therapeutic response.

The construction of the New Brunswick Center for Precision Medicine adjacent to the Dr. Georges-L-Dumont is almost completed and will open in the Fall of 2018. We wish to thank our partners, the Université de Moncton and the Vitalité Health Network, for their help in finding the necessary funding for this cutting-edge infrastructure.

Many elements, such as our team’s expertise, motivation and passion, are required to achieve the level of success that ACRI has come to know and such achievements would not be within our reach today, without the support of the community, our donors and stakeholders.
MESSAGE FROM THE CHAIR OF THE BOARD OF DIRECTORS ADMINISTRATORS

This year marks the 20th anniversary of the Atlantic Cancer Research Institute. I take great pride in having had the privilege to work with members of ACRI’s management and research teams over the years. It has really been exciting to watch ACRI’s research and management team at work. This has only strengthened my confidence as well as my belief in the important work they are accomplishing.

The construction of a new specialized research center which will be completed in the Fall of this year will help ACRI’s research team in its continuing quest to find solutions to the terrible disease that is cancer with a continued focus on collaboration to improve outcomes for cancer patients.

I would like to take this opportunity to thank the community of Atlantic Canada for their generosity and continuous support. I would also like to thank the Université de Moncton and the Vitalité Health Network for their help and collaboration, as well as all of our others partners.

Finally, I would like to thank the members of the Board of Directors for their dedication and contribution to the success of the ACRI.
ACRI CONTINUES TO FOCUS its major research efforts on investigating its liquid biopsy-enabling technologies and the identification of novel therapeutic strategies for cancer;

PUBLICATIONS IN THE PAST YEAR highlight new knowledge and downstream applications for liquid biopsy that utilize ACRI’s proprietary Vn96 peptide for extracellular vesicle (EV) isolation;

RESEARCH REPORTS ALSO SHOW PROGRESS of ACRI scientists in understanding the underlying mechanisms that contribute to cancer development and progression.

SELECTED PUBLICATIONS

ACRI PUBLICATIONS 2017-2018


TECHNOLOGY TRANSFER UPDATE

PATENTS
- The Vn96 EV isolation technology European Patent has been granted as of December 27, 2017
- The Vn96 EV isolation technology Canadian Patent prosecution is ongoing
- The Polysaccharide EV isolation method patent has received a notice of allowance from the European Patent Office
- The Polysaccharide EV isolation method patent prosecution in the United States is still ongoing
- ACRI is about to file a provisional patent for a new EV isolation method
- ACRI’s microwave ablation technology patent application is about to enter the national phase

LICENSING
- ACRI has entered into a commercialization agreement with Exosomics, backed by Lonza, Italy
- ACRI has licensed exclusively its microwave ablation technology to MIMA-PRO, backed by Vison, China

“Our liquid biopsy technology allows doctors to start with a patient’s blood or urine sample and determine, in real-time, the current state of an ever-changing disease like cancer.”

– Dr. Rodney Ouellette, President & Scientific Director
A GROWING FAMILY

TEAMS BY INITIATIVES:

LIQUID BIOPSY & EV THERAPEUTICS
BJI ANISH, MSc
CRAIG AYRE, PhD
AMRITA BASU, PhD
SURENDAreddY DHADI, PhD
NAGUFAL EL BEKKOURI, MSc Candidate
SEBASTIEN FOURNIER, BSc
ANIRBAN GHOSH, PhD
ROSTYSLAV HORBAY, PhD
AWANIT KUMAR, PhD
JEREMY ROY, PhD
CATHERINE TAYLOR, MSc

MICROWAVE-ASSISTED TUMOUR ABLATION TECHNOLOGIES
ALEXANDRE ARSENEAU, MASC Candidate
JACQUELINE BÉLANGER, PhD
DELPHINE FOUCHER, PhD
JOCELYN PARÉ, PhD, MSM
MARC-ANDRÉ RICHARD, MASc Candidate
ANTHONY THÉRIAULT

PROTEOMICS & MASS SPECTROMETRY
DAVID BARNETT, PhD
ANDREW JOY, MSc
MAI NGOC-NU, BSc

NEXT-GENERATION SEQUENCING
SIMI CHACKO, MSc
JACYNTH LACROIX, MSc

BIOINFORMATICS
ILLYASS HAJI, MSc
DANIEL LÉGER, MSc
GABRIEL WAINBERG, PhD

CELLULAR MECHANISMS
IOANNA AMRATA, Postdoctoral fellow
AMIT BERA, PhD
NADIA BOUHAMDANI, PhD Candidate
SURENDAR REDDY DHADI, PhD
NAOUFAL EL BEKKOURI, MSc Candidate
SEBASTIEN FOURNIER, BSc
ANIRBAN GHOSH, PhD
ROSTYSLAV HORBAY, PhD
AWANIT KUMAR, PhD
JEREMY ROY, PhD
CATHERINE TAYLOR, MSc

SYNTHETIC LETHALITY
LAURA AYRE, BSc
CHARLES BULLERWELL, PhD
NICHOLE CUMBY, PhD
PIERRE DEPREZ, PhD
MAX MERLOVICH, MSc
ERIC MERZETTI, PhD

ANTHONY THÉRIAULT

MANAGEMENT:

STÉPHANIE ALBERT – Executive Assistant
HAI LEQUANG, CPA, CA, MSc – Director of Finance & Administration
STEPHEN LEWIS, PhD – Assistant Scientific Director
MARK MACDONALD, MSc – Laboratory Operations Manager
NADINE MARTIN, MBA – Communications Agent
RENÉE MCLAREN, BA – Human Resources & Administration Officer
RODNEY J. OUELLETTE, MD, PhD – President & Scientific Director
REMI RICHARD, MSc, MBA – Business Development Officer
### Statement of Operations

**Year ended March 31, 2018**

#### REVENUES

- Research & Government Grants: $3,058,585
- Fundraising Campaign & Other Donations: $624,113
- Research & Medical Services Rendered: $1,561,017
- Others: $75,021
- **TOTAL: $5,318,736**

#### EXPENSES

- Salaries & Benefits: $2,587,942
- Laboratory Supplies: $1,094,108
- Administration & Overhead Expenses: $1,404,200
- **TOTAL: $5,086,250**

#### EXCESS OF REVENUES OVER EXPENSES

- **$232,486**

### Balance Sheet

**As of March 31, 2018**

- Current Assets: $3,584,891
- Capital Assets: $4,330,467
- Total Liabilities: $2,308,145
- **NET ASSETS OR EQUITY: $5,607,213**